Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Novo Nordisk A/S
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
BerGenBio ASA
IRCCS San Raffaele
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
University of Washington
Children's Oncology Group
University of Washington
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Duke University
National Cancer Institute (NCI)
Bio-Path Holdings, Inc.
Poitiers University Hospital
St. Jude Children's Research Hospital
Pfizer
Baylor College of Medicine
Aileron Therapeutics, Inc.
University of Maryland, Baltimore
Mayo Clinic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Heidelberg University
University of Washington
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Hospital Israelita Albert Einstein
Stichting Hemato-Oncologie voor Volwassenen Nederland
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Children's Oncology Group
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis